Drug Profile
Etanercept biosimilar - Pfizer
Alternative Names: LifmiorLatest Information Update: 17 Nov 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
Most Recent Events
- 15 Dec 2016 Committee for Medicinal Products for Human Use (CHMP) of EMA recommends approval of Etanercept biosimilar for Rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis, Plaque psoriasis (In children, In adolescents and In adults), Ankylosing spondylitis and Non-radiographic axial spondyloarthritis in European Union
- 14 Dec 2016 Preregistration for Rheumatoid arthritis, Plaque psoriasis (In children, In adolescents, adults), Non-radiographic axial spondyloarthritis, Ankylosing spondylitis, Psoraitic arthritis and Juvenile rheumatoid arthritis in European Union (SC) before December 2016